R. Decastro

发表

The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.

G. Beck, T. Raffin, Jar‐Chi Lee, 2006, American journal of respiratory and critical care medicine.

Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome.

M. Raffeld, S. Holland, J. Moss, 2008, American journal of respiratory and critical care medicine.

Meningiomas in lymphangioleiomyomatosis.

N. Patronas, J. Moss, Joel Moss, 2001, JAMA.

AMD3100 is a potent antagonist at CXCR4R334X, a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome

D. McDermott, H. Malech, P. Murphy, 2011, Journal of cellular and molecular medicine.

Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis.

J. Moss, Ji-an Wang, J. McCoy, 2004, Proceedings of the National Academy of Sciences of the United States of America.

CT of pleural abnormalities in lymphangioleiomyomatosis and comparison of pleural findings after different types of pleurodesis.

A. Dwyer, J. Moss, N. Avila, 2006, AJR. American journal of roentgenology.

The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

T. Fleisher, D. Kuhns, D. McDermott, 2011, Blood.

carboxy-tail of chemokine receptor CXCR4 WHIM syndrome caused by a single amino acid substitution in the

D. Wechsler, D. McDermott, H. Malech, 2013 .

WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.

D. Wechsler, D. McDermott, H. Malech, 2012, Blood.

Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease.

S. Holland, K. Sullivan, A. Zelazny, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Macrocephaly associated with the DICER1 syndrome

Gretchen M. Williams, D. Stewart, Y. Messinger, 2016, Genetics in Medicine.

syndrome with the CXCR4 antagonist plerixafor A phase 1 clinical trial of long-term, low-dose treatment of WHIM

S. Pittaluga, D. Kuhns, D. McDermott, 2014 .

with WHIM syndrome The CXCR4 antagonist plerixafor corrects panleukopenia in patients

D. Kuhns, P. Murphy, R. Decastro, 2012 .

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

S. Pittaluga, T. Fleisher, D. Kuhns, 2014, Blood.

Quantification of Thyroid Cancer and Multinodular Goiter Risk in the DICER1 Syndrome: A Family-Based Cohort Study

Gretchen M. Williams, M. Lodish, D. Stewart, 2017, The Journal of clinical endocrinology and metabolism.

Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort

P. Rosenberg, S. Savage, J. Peters, 2016, Cancer.

Baseline cancer screening findings from the NCI Li-Fraumeni syndrome study.

S. Savage, J. Peters, P. Mai, 2016 .

Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort

D. Bluemke, S. Savage, J. Peters, 2017, JAMA oncology.

Successful Control of Preexistent Active Infection by Granulocyte Transfusions During Conditioning Induced Cytopenia In Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Stem Cell Transplant

N. Theobald, H. Malech, S. Leitman, 2010 .

The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

T. Fleisher, D. Kuhns, H. Malech, 2011, Blood.